Setback for Novartis drug in advanced lung cancer trial

Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer when compared to just chemotherapy alone.